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Gene therapy is a promising approach for treating a spectrum of neurological and
neurodegenerative disorders by delivering corrective genes to the central nervous system
(CNS). In particular, adeno-associated viruses (AAVs) have emerged as promising tools for
clinical gene transfer in a broad range of genetic disorderswith neurological manifestations.
In the current review, we have attempted to bridge our understanding of the biology
of different AAV strains with their transduction proﬁles, cellular tropisms, and transport
mechanisms within the CNS. Continued efforts to dissect AAV-host interactions within
the brain are likely to aid in the development of improved vectors for CNS-directed gene
transfer applications in the clinic.
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INTRODUCTION
Numerous congenital disorders exhibit distinct manifestations
in the central nervous system (CNS). Loss of functionality in
affected cell types within the brain can often be attributed to
defects in single genes. For instance, a range of neurological
disorders arise from the inability of cells in the CNS to break
down metabolic end products [e.g., lysosomal storage disorders
(LSDs)]. One such example of LSDs with fatal manifestations
includes globoid-cell leukodystrophy (GLD) or Krabbe disease
in which mutations in galactosylceramidase leads to accumula-
tion of the toxin “psychosine” in the CNS (Wenger et al., 2002).
This disease shows early onset of symptoms like demyelination,
astrocyte gliosis etc., and progresses to the death of patients
within 2 years of age (Lin et al., 2005). Other examples of LSDs
include Fabry disease, Gaucher disease, GM1/GM2 gangliosidosis,
mucopolysaccharidoses disorders, Pompe disease, and neuronal
ceroid lipofuscinosis amongst others (Boustany, 2013; Simonato
et al., 2013).
Another broad category is neurodegenerative disorders, where
functionally distinct neuronal subpopulations are lost due to
genetic predispositions or environmental toxins. Commonly
known examples of this category include dopaminergic (DA) neu-
ronal loss in Parkinson’s disease and GABAergic neuronal loss in
Huntington’s disease (Orr and Zoghbi, 2007; Irwin et al., 2013). A
common feature for most of these diseases is severe impairment
of combinations of cognitive, motor and sensory functions, lead-
ing to loss of quality of life and ultimately death of the patients.
Gene therapy holds promise for treating these severely debilitat-
ing disorders by delivering healthy cargo of genetic information
to speciﬁc cell types in the CNS. In particular, adeno-associated
viruses (AAVs) have emerged as promising tools for clinical gene
transfer in a broad range of genetic disorders with neurological
manifestations (Gray, 2013). In this review, we have attempted to
bridge our understanding of the capsid biology of different AAVs
with their properties such as transduction efﬁciencies, cellular
tropism and transport within the CNS.
RECOMBINANT ADENO-ASSOCIATED VIRAL VECTORS
Adeno-associated viruses are non-enveloped, helper-dependent
parvoviruses with an icosahedral capsid architecture ∼25 nm in
diameter. AAVs package ∼4.7 kb genome ﬂanked by ∼145 bp
inverted terminal repeats (ITRs) on the 5′ and 3′ ends (Bowles
et al., 2006). The wildtype AAV (wtAAV) genome is a linear sin-
gle stranded DNA consisting of two open reading frames (ORFs).
AAV ORFs encode four replication proteins (Rep) and three cap-
sid proteins (Cap/VP) and an assembly activating protein (AAP;
Agbandje-McKenna and Kleinschmidt, 2011). In addition, wtAAV
requires co-infection by adenoviruses or herpes simplex viruses
(HSVs) for successful replication and production of viable AAV
particles (Bowles et al., 2006). Three advancements have been
instrumental in enabling the use of AAV as a recombinant vec-
tor for gene transfer applications: (a) the ability to pseudotype
AAV vectors by employingAAV capsids of natural or synthetic ori-
gin (Gao et al., 2002, 2004; Rabinowitz et al., 2002; Vandenberghe
et al., 2009); (b) cloning and characterization of adenoviral helper
genes that are minimally required for generation of infectious
AAV particles (Xiao et al., 1998); and (c) understanding that ITRs
are the only cis-acting molecular signature for successful pack-
aging of a transgene within an AAV capsid (Xiao et al., 1997).
These streamlined components are now used to manufacture
recombinant AAV (rAAV) vectors packaging a broad spectrum
of promoter elements and transgene cassettes for different gene
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transfer applications (Grieger et al., 2006). It is noteworthy that
due to the aforementioned discoveries, we are now able to manu-
facture AAV vectors with minimal contamination of the wildtype
virions.
Different AAV serotypes exhibit a range of properties pertain-
ing to antigenicity, in vivo tropism and receptor interactions based
on their capsid structures (Agbandje-McKenna and Kleinschmidt,
2011). Capsids of differentAAV strains bind a spectrumof cell sur-
face glycan receptors and utilize co-receptors for infection (Huang
et al., 2014). These differences in capsid-receptor interactions play
a major role in determining the regional and cellular transduction
efﬁciencies of AAV strains across different mammalian organs.
Continued progress in understanding the biology of AAV infec-
tion over the past two decades has provided the scientiﬁc and
clinical community with an arsenal of AAV strains that offer desir-
able features for CNS gene transfer (Lentz et al., 2012). In addition
to natural isolates, several laboratory-derived AAV strains have
been engineered or evolved for speciﬁc CNS gene transfer appli-
cations. These efforts have yielded novel AAV vectors for targeting
(a) glioblastoma cells (Maguire et al., 2010); (b) rat, mouse and
human neural stem cells (Jang et al., 2011); and (c) speciﬁc regions
(piriformcortex and ventral hippocampus) of blood–brain barrier
(BBB) compromised rats (Gray et al., 2010). We discuss the exist-
ing inventory of AAV vectors and their characterization within the
CNS below.
BIOLOGY OF AAV CELL ENTRY AND IMPLICATIONS FOR CNS
GENE TRANSFER
Successful transduction by AAV vectors is contingent on many
key steps like cell surface receptor binding, endocytic uptake,
endosomal escape, subsequent nuclear entry, capsid uncoating,
genome release, second strand synthesis, and subsequent tran-
scription. Surface exposed regions on the AAV capsids dictate
the interactions with the host cell surface (Huang et al., 2014).
Cell surface glycans have been identiﬁed as the preferred primary
receptors for many natural AAVs (Asokan et al., 2012). Accord-
ingly, differences in glycan architecture have been attributed to
variations in the efﬁciency of gene transfer by AAV capsids in dif-
ferent organs. AAV serotypes 1, 5, and 6 bind N-linked sialic acid
(SA), whereas AAV4 is the only natural AAV isolate that binds
O-linked SA moieties on mammalian cell surfaces (Kaludov et al.,
2001; Walters et al., 2001; Wu et al., 2006b). AAV2, three and six
bind heparan sulfate (HS) proteoglycans, whereas AAV9 requires
N-terminal galactose residues to perform successful gene transfer
(Summerford and Samulski, 1998; Handa et al., 2000; Bell et al.,
2011; Shen et al., 2011). Direct injection of HS binding AAV2 in
the CNS leads to a largely neuronal transduction proﬁle, whereas
SA binding vectors like AAV1 and AAV5 perform efﬁcient neu-
ronal and some glial transduction (Bartlett et al., 1998; Davidson
et al., 2000; Mandel and Burger, 2004). The preferential neuronal
tropismofAAV2was later identiﬁed to correlatewith the compara-
tively larger availability of heparan sulfate proteoglycans (HSPGs)
on the surface of neurons than glia (Hsueh et al., 1998; Hsueh
and Sheng, 1999). Interestingly, in addition to enabling the neu-
rotropic bias of AAV2, HS binding has also been associated with
restriction of the CNS volume that is effectively targeted by AAV
vectors.
It is now known that the lysine residue at position 531 onAAV6
capsid plays an indispensable role in HS binding (Kawamoto et al.,
2005; Wu et al., 2006a). By creating HS binding and non-binding
variants of AAV1 (AAV1E531K) and AAV6 (AAV6K531E) respec-
tively, Arnett et al. (2013) demonstrated antagonistic effect of HS
bindingonCNS transductionof intracranially injectedAAVs. Sup-
porting these point mutation studies, co-injection of safe doses of
soluble heparin also led to substantial increase in CNS transduc-
tion by AAV2 (Nguyen et al., 2001; Mastakov et al., 2002). On the
other hand, N-terminal galactose binding AAV9 is one of the most
efﬁcient vectors for CNS gene transfer. AAV9 has been shown to
perform extensive neuronal and glial transduction from differ-
ent routes of injection in small and large animal models (Cearley
and Wolfe, 2007; Foust et al., 2009; Bevan et al., 2011; Dayton
et al., 2012;Ahmed et al., 2013; Benkhelifa-Ziyyat et al., 2013; Iwata
et al., 2013; Yamashita et al., 2013). In addition to important fea-
tures on the capsid surfaces, efﬁciency of AAV vector mediated
gene transfer can be affected by several post-entry, trafﬁcking and
genome-related events within the CNS. Studies pertaining to some
of these aspects of AAV biology have been performed within the
context of the CNS and discussed later. First we discuss how differ-
ent AAV strains are inﬂuenced by the route of CNS administration
below.
DIRECT AAV ADMINISTRATION INTO THE CNS
Direct injections of AAV into the CNS have been used to achieve
high levels of transgene expression across different animal mod-
els (McCown et al., 1996; Chamberlin et al., 1998; Tenenbaum
et al., 2004; Bockstael et al., 2012). This strategy of AAV vector
administration can be broadly classiﬁed into intra-cerebrospinal
ﬂuid (CSF) administration and intra-parenchymal administra-
tion. The CSF plays amulti-functional role by providing nutrients;
molecular and physical cues for important processes like stem
cell migration; and removal of interstitial solutes from the brain
parenchyma (Sawamoto et al., 2006; Iliff et al., 2012). The CSF is
housed within the subarachnoid space, cerebral ventricles, cis-
terna magna and openings under the cerebellum (foramena),
and is in close contact with the spinal cord and brain tissue
in the rostrocaudal axis (Koh et al., 2005; Lehtinen et al., 2013).
Understandably, efﬁcient delivery of reporter/therapeutic trans-
genes to large areas of the CNS has been achieved using AAV
injections into cerebral ventricles, cisterna magna, or intraverte-
bral lumbar puncture (Davidson et al., 2000; Passini and Wolfe,
2001; Fu et al., 2003, 2007; Liu et al., 2005b; Cabrera-Salazar et al.,
2010; Glascock et al., 2012; Raﬁ et al., 2012; Samaranch et al.,
2012, 2013; Chakrabarty et al., 2013). Serotypes such as AAV9
and rh.10 exhibit inherently superior ability to spread within
the brain parenchyma. These vectors have been used to achieve
widespread and long term expression of corrective transgenes
from intra-CSF injections toward disease models of spinal muscu-
lar atrophy and Krabbe disease (Glascock et al., 2012; Raﬁ et al.,
2012). On the other hand, some AAV vectors exhibit highly
cell-speciﬁc transduction proﬁles from intra-CSF injections. For
instance, intracerebroventricular (ICV) administration of AAV4
leads to selective targeting of astrocytes in the k zone surrounding
the cerebral ventricles (Davidson et al., 2000; Liu et al., 2005a,b).
The ependyma consists of adult neural stem cells that have the
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ability to perform lifelong migration, differentiation and repopu-
lation of functionally deﬁned regions in the brain (Alvarez-Buylla
and Lim, 2004). Indeed, targeted delivery of neurogenic cargo,
e.g., noggin and brain derived neurotrophic factor (BDNF) pack-
aged in AAV4 has shown long-term rescue of mouse models of
severely debilitating CNS disorders like Huntington’s disease (Liu
et al., 2005b; Benraiss et al., 2012). In addition to these in vivo
studies, biophysical analysis of the AAV4 capsid has revealed dis-
tinct structural features and low capsid homology among other
natural AAV isolates (Padron et al., 2005; Govindasamy et al.,
2006).
Due to the advantages offered by the CSF connectivity of the
brain and the spinal cord,AAV vector administration has also been
extensively characterized through intrathecal injections (ITs). Tra-
ditionally, these injections have been performed by exposing the
subarachnoid space at the suboccipital cisterna magna region or
the intravertebral space at lumbar region. In general, applications
requiring enhanced transduction at the motor, sensory and noci-
ceptive neuronal subpopulations [e.g., within dorsal root ganglia
(DRG)] utilize lumbar punctures. AAV serotypes 1, 5, 8, and 9
have shown extensive transduction in the spinal cord and DRG
neurons from IT injections at the intravertebral lumbar region
(Vulchanova et al., 2010; Hirai et al., 2012; Jacques et al., 2012). In
an independent study, Snyder et al. (2011) compared IT injections
of AAV vectors 1, 6, 8, and 9 for transduction of motor neurons
in the spinal cord and brain stem, and reported superior trans-
duction properties of AAV6 and 9. From studies conducted in
large animals like pigs and non-human primates (NHPs), a sin-
gle IT injection of AAV9 has emerged as the candidate procedure
for clinical correction of motor neuron disorders affecting the dif-
ferent regions of the spinal cord (Federici et al., 2012; Gray et al.,
2013). As with all these studies, it remains to be seen how vec-
tors pseudotyped with these different capsids respond in a human
setting and more importantly, in manifestations of human brain
disease.
Direct parenchymal injections of AAV vectors in rodents and
NHPs have been traditionally used to achieve transduction within,
focused, spatio-functionally distinct regions of the brain (Burger
et al., 2004; Lin et al., 2005; Cearley and Wolfe, 2006). AAV2
shows minimal ability to spread from the parenchymal site of
injection and performs preferential gene transfer in the neurons
(Davidson et al., 2000). Unlike other capsid-receptor interactions,
the high afﬁnity for HSPGs has been shown to be detrimental
to the spread of AAV2 in the brain parenchyma (Mastakov et al.,
2002). As discussed earlier, another vector that lacks the ability
to spread from the site of intracerebral injection is the NHP iso-
late AAV4 (Davidson et al., 2000). In another study performed
in adult rats, Burger et al. (2004) demonstrated that N-linked
SA binding AAV1 and AAV5 are superior to AAV2 in terms of
spread of transduction from a single parenchymal microinjection
into the hippocampus, substantia nigra, globus pallidus, stria-
tum, and spinal cord. Widespread transgene expression was also
achieved by parenchymal injections of AAV7, 8 and 9 in rodents
(Broekman et al., 2006; Cearley and Wolfe, 2006). On a cellular
level, these vectors preferentially transduced neurons in the adult
rodents from clinically relevant stereotaxic injections into the hip-
pocampus, thalamus, cortex and striatum (Cearley and Wolfe,
2006). Interestingly, in addition to capsid serotype, other param-
eters like age of the animal also seem to affect cellular tropism
of AAV vectors from direct brain injections. Using ICV injec-
tions of AAVs 1, 8, and 9, Chakrabarty et al. (2013) demonstrated,
that injections performed on postnatal day 0 (P0) leads to pref-
erential neuronal tropism. On the other hand the same vectors
showed neuronal and astrocytic transduction proﬁles from injec-
tions performed on P1 or later. Against this backdrop of AAV
isolates and serotypes that have been extensively characterized
for their receptor interactions, novel AAV serotypes isolated from
human beings – AAVhu32, 37, 11, 48R3; and NHPs – AAVrh.8
and 10 have been evaluated in neonatal and adult rodents (Cear-
ley andWolfe, 2007; Cearley et al., 2008). Preliminary studies have
conﬁrmed the ability of these vectors to perform transduction
comparable to AAV9 in rodents, expanding the AAV vector toolkit
for CNS gene transfer. For instance, a recent study conducted
head to head comparison of AAV 2, 5, 8, and rh.10 for thera-
peutic delivery of functional “CLN2” transgene in a late infantile
neuronal ceroid lipofuscinosis (LINCL) mouse model. Among
different serotypes, AAVrh.10 demonstrated comparatively larger
spread of transgene expression and restoration of functional levels
of the enzyme tripeptidyl-peptidase I, originally lost as a result
of mutations in the CLN2 gene. Improvement in motor activi-
ties like gait, balance and grip; and amelioration of seizures led to
enhanced survival of the treated mice from a single direct brain
parenchymal injection (Sondhi et al., 2007). More recent studies
evaluating AAVrh.10 administered through different routes in pri-
mates have been reviewed in detail in the context of AAV transport
within the CNS below.
INTRAVENOUS ADMINISTRATION OF AAV VECTORS FOR
CNS GENE TRANSFER
Systemic administration of vectors has the potential to achieve
ubiquitous gene transfer of the CNS from a single injection.
Additionally, the minimally invasive nature of intravenous (IV)
injections adds value to clinical administration of AAV vectors
via the bloodstream. Two major roadblocks currently impede
our ability to utilize this technique for therapeutic gene transfer
of the CNS. The ﬁrst major concern is the broad biodistribu-
tion of AAV vector particles into off-target tissues such as the
liver, spleen and kidneys during IV administration of AAVs. For
instance, IV injections of AAV9 achieves exceptional transduc-
tion of neurons and glia in rodents and NHPs, but also leads
to enrichment of viral genomes (∼10 fold or more) in the liver
and spleen as compared to the brain (Gray et al., 2011). Care-
ful optimization and use of safe dosages of AAV vectors can lead
to reduced systemic leakage and associated viral clearance due to
neutralizing antibodies (Gray et al., 2011). Another approach to
reduce peripheral organ toxicity is the occlusion of blood ﬂow
into organs like liver and spleen during IV injections of AAVs
(Bevan et al., 2011). Clearly, the use of such techniques requires
meticulous optimization of complicated surgical procedures dur-
ing vector administration before being approved for the clinic.
However, it should also be noted that several of these tech-
niques are already approved for use with other drugs/treatments in
the clinical setting. Another important problem is the inability of
the majority of well-characterized AAV vectors to efﬁciently cross
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the BBB and transduce cells within the CNS. In order to success-
fully transduce cells in the CNS, systemically injected virions are
thought to undergo receptormediated transport to cross the brain
microvasculature. However, the exact mechanism(s), paracellular
or transcellular remain to be determined. Tight junctions in the
endothelial cells, astrocytic endfeet and pericytes are known to col-
lectively constitute the BBB (Zhang et al., 2011; Yang et al., 2014).
Intra-arterial infusion of mannitol leads to transient opening of
the BBB without eliciting any permanent damage (Fu et al., 2003).
Short-term disruption of these checkpoints by administration of
mannitol led to effective CNS transduction by IV injections of
AAV2 which is unable to cross the BBB (Fu et al., 2003; McCarty
et al., 2009).
A recent study compared CNS transduction from injections
of AAVs 1, 2, 5, 6, 7, 9, Rh.10, Rh.39, and Rh.43 into the
superﬁcial temporal vein of neonatal mice (P1). Successful, but
differential levels of CNS transduction were reported from all
tested vectors (except AAVs 2 and 5; Zhang et al., 2011). Addi-
tionally, some leading examples of AAV vectors that have been
tested in adult rodents and NHPs include AAVs 8, 9, Rh.8, and
Rh.10 (Shen et al., 2013; Yang et al., 2014). These results clearly
indicate that many AAV serotypes have been associated with a
range of cellular and regional CNS gene transfer properties from
systemic injections. In this regard, a better understanding of cap-
sid structural motifs that allow certain AAV strains to traverse
the BBB is critical. For instance, using directed evolution, Gray
et al. (2010) have engineered two AAV capsids capable of crossing
seizure compromised-BBB in rats. The original library of AAVs
from which the candidate capsid was isolated included AAVs 1–6,
8, and 9. Careful assessment of the parental and evolved cap-
sid sequences might provide further insights into capsid domains
possibly involved in CNS transduction after IV administration
(Gray et al., 2010). Along similar lines, peptide motifs have been
identiﬁed that impart AAV capsids with the ability to cross the
brain microvasculature. IV injection of a peptide modiﬁed ver-
sion of the AAV2 packaging β-glucuronidase was used to achieve
signiﬁcant clearance of lysosomal storage burden, leading to cog-
nitive beneﬁts and prolonged survival in a mucopolysacharidoses
VII mouse model (Chen et al., 2012). It is noteworthy that IV
administration of the corrective transgene packaged in AAV9 cap-
sid was unable to confer therapeutic beneﬁts. It was later identiﬁed
using ﬂuorescein labeled Sambucus nigra lectin that enhanced
SA depositions in the MPS VII affected mouse CNS might be
detrimental for AAV9-mediated CNS transduction (Chen et al.,
2012). Such results demonstrate that the biology of different AAV
strains can be affected by speciﬁc disease phenotypes that alter
the molecular composition(s) of different cell types within the
brain.
AAV TRANSPORT WITHIN THE CNS
Subsequent to vector administration and engagement of cell sur-
face attachment factors such as glycans, AAV vectors appear to
undergo interstitial as well as intracellular transport within the
CNS. For instance, recent studies in the primate brain have
demonstrated that AAVrh.10 displays distinct transduction pat-
terns following different routes of administration (Rosenberg
et al., 2014). Of the ﬁve routes tested, delivery to parenchyma
resulted in more efﬁcient gene transfer than intraventricular or
intraarticular routes of administration. Another study in mar-
mosets demonstrated that IV administration of AAVrh.10 is
capable of efﬁcient CNS transduction (Yang et al., 2014). These
results highlight the potential diversity in AAV vector transport
mechanisms not only in the context of brain physiology, but
also possibly due to vector serotype, receptor usage and animal
models. Although not completely understood, two mechanisms,
namely paravascular CSF transport and axonal transport appear
to play a role in controlling the spread of AAV vectors within
the CNS. It has been established that the paravascular transport
of CSF plays a major role in the spread of interstitial ﬂuid (ISF)
within the CNS. One of the earliest studies demonstrated that pro-
teins accumulate along highly vascularized regions of forebrain
and brainstem within minutes of ICV injections (Rennels et al.,
1985). Further, medically induced blood pressure ﬂuctuations
have been directly shown to control the spread of nanoparti-
cles including AAVs in the brain (Hadaczek et al., 2006). The
brain is distinct from other organs in that it lacks lymphatic
circulation (Cserr et al., 1992; Abbott, 2004). To understand
compensatory mechanisms, Iliff et al. (2012) performed CNS-
injections of differently sized (between 750 da and 2000 kda)
molecular tracers. Using compelling visual evidence provided by
2-photon microscopy, the authors concluded that paravascular
movement of CSF clears solutes from the CNS (Iliff et al., 2012).
Speciﬁcally, the para-arterial inﬂux and the paravenous efﬂux of
subarachnoid CSF drain accumulations of metabolic end prod-
ucts and other solutes within the brain parenchyma. These results
suggest that mechanisms like the CSF transport can possibly play
a role in determining the extent of spread of viruses within the
CNS. Clearly, understanding the structure-function correlates of
AAV capsids and host factors that might dictate their ability to
spread in the brain against the backdrop of CNS physiology will
be valuable.
Another known pathway that viruses utilize to spread within
the CNS is axonal transport post-entry into host neurons. Viruses
can travel long distances by getting transported across synaptic
connections in various sectors of mammalian central and periph-
eral nervous system (Beier et al., 2011; Taylor et al., 2012). Over
the years, HSV and pseudorabies virus (PRV) have been used
to visualize axonal transport and the resulting patterns of viral
infections in the CNS milieu (Granstedt et al., 2013). Although
accurate neuronal tracing has been achieved using these viruses,
a major disadvantage is the loss of gene expression and neu-
ronal death observed in the labeled cells between 5 days and
2 weeks post-infection (Wickersham et al., 2007; Osakada et al.,
2011; Rothermel et al., 2013). In case of AAVs, both unidirectional
and bidirectional axonal transport has been observed depend-
ing on the viral strain (Hollis et al., 2008; Salegio et al., 2013).
During retrograde transport, intact virions are taken up at the
axonal projections and are transported to the neuronal cell body
(soma), where the virus enters the nucleus to perform trans-
duction. Conversely, a successful anterograde transport requires
virions to enter the neuronal soma and travel along the length of
the axon to ﬁnally get released at the projections. The released
virions are then free to transduce new cellular subpopulations in
the region.
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Understandably, directional axonal transport of AAV can be
utilized to achieve safe and targeted gene delivery in spatially and
functionally distinct neuronal subpopulations. For instance,AAV2
speciﬁcally undergoes anterograde transport (Kells et al., 2009;
Ciesielska et al., 2011). On the other hand,AAV6 exhibits exclusive
retrograde transport in both rat and primate brain (San Sebastian
et al., 2013). In addition, AAV9 has been shown to efﬁciently travel
in both anterograde and retrograde directions (Masamizu et al.,
2011; Low et al., 2013; Castle et al., 2014b). Speciﬁcally, Castle
et al. (2014b) visualized dye-conjugatedAAV9 vectors during their
anterograde and retrograde movements within cultured rat corti-
cal neurons. These studies showed that axonal transport of AAV9
occurs in Rab7 positive late endosomal/lysosomal compartments.
Further, cytoplasmic dynein and kinesin-2 were identiﬁed as
being critical for successful retrograde and anterograde transport,
respectively (Castle et al., 2014a,b).
SAFETY ASPECTS
Recombinant AAV vector genomes display inefﬁcient integra-
tion into the host chromosome and predominantly persist in
episomal form (McCarty et al., 2004). This reduces the risk of
insertional mutagenesis, often associated with other viral vec-
tors like retroviruses (Bokhoven et al., 2009). The vector genomes
subsequently require the host cellular machinery to carry out
second strand synthesis, transcription and translation (Duan
et al., 1998; Nash et al., 2008). Safety aspects pertaining to per-
sistence of AAV vector genomes in the CNS are forthcoming
and have been reviewed in general elsewhere (McCarty et al.,
2004; Lentz et al., 2012; Dismuke et al., 2013). Another impor-
tant safety consideration is the observation that rAAV mediated
overexpression of non-self transgenes can elicit immune responses
due to antigen presentation of the expressed transgene product.
For instance, direct primate brain infusion of AAV1 packaging a
humanized Renilla GFP transgene triggered an immune response
against the translated reporter product (Hadaczek et al., 2009).
Similarly, a cell mediated immune response and neuronal loss
was observed in rats injected with AAV9 vectors packaging the
GFP reporter transgene or a human L-amino acid decarboxy-
lase transgene (Ciesielska et al., 2013). More recently, certain AAV
serotypes have been shown to undergo systemic leakage result-
ing in off-target biodistribution in organs like liver and spleen
(Gray et al., 2011; Rosenberg et al., 2014; Yang et al., 2014). These
preliminary observations in animal models highlight the need
to better understand the parameters that determine potential
toxicity/biodistribution proﬁles and immune response in AAV-
mediated CNS gene transfer. It is also important to acknowledge
that aspects related to manufacturing, downstream processing
and purity of AAV vector preparations are critical toward ensur-
ing the safety of AAV vectors. A comprehensive comparison of
different viral gene transfer vectors for parameters such as pack-
aging capacity, host chromosomal integration and other biosafety
aspects can be found elsewhere (Lentz et al., 2012; Dismuke et al.,
2013).
SUMMARY
As of early 2014, 5.3% of world-wide clinical trials involving gene
therapy have utilized AAV vectors (109 ongoing trials; Journal of
Gene Medicine). Only a few of these trials are aimed at treating
diseases with CNS manifestations. In the current review, we have
attempted toprovide anoverviewof various parameters thatmight
play a role in determining the success of AAVmediated therapeutic
gene transfer to the CNS. Interactions of AAV vectors with differ-
ent primary receptors, directional transport and cellular tropisms
following different routes of administration are summarized in
Table 1. Although we were unable to cover every contribution
to the ﬁeld of CNS gene therapy, we hope that the information
Table 1 | Capsid-receptor interactions, transduction profiles, and axonal transport properties of some of the well-characterized adeno-associated
viral serotypes in the mammalian CNS.
Serotype Primary receptor Intra-CSF or intra-parenchymal
administration









AAV1 α2,3/α2,6 N -linked SA ++ + + + A–,R+
AAV2 Heparan sulfate + – – – A+,R–
AAV4 α2,3 O-linked SA – + – – ?
AAV5 α2,3 N -linked SA ++ + – – ?
AAV6 α2,3/α2,6 N -linked
SA/heparan sulfate
++ – + + A–,R+
AAV8 ? ++ ++ ++ ++ A+, R+
AAV9 Galactose +++ ++ +++ +++ A+,R+
AAVRh.8 ? ++ ++ +++ +++ ?
AAVRh.10 ? +++ + +++ +++ ?
? Receptor usage/axonal transport has not been characterized; + low levels of transduction; ++ moderate levels of transduction; +++ high levels of transduction; –
no transduction; ? A+ or R+ (AAV vector undergoes axonal transport in the anterograde (A) or retrograde (R) direction during in vivo characterization).
Frontiers in Molecular Neuroscience www.frontiersin.org September 2014 | Volume 7 | Article 76 | 5
Murlidharan et al. AAV biology in the CNS
provided in this review not only highlights potential gaps in our
understanding of AAV-host interactions within the CNS, but will
assist with continued vector development for CNS-directed gene
transfer applications in the clinic.
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